Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001545:Benserazide / Q000494:pharmacology*; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology*; D007980:Levodopa / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008711:Metergoline / Q000008:administration & dosage / Q000494:pharmacology*; D008784:Methysergide / Q000008:administration & dosage / Q000494:pharmacology*; D008875:Middle Aged; D010902:Pituitary Gland / Q000378:metabolism*; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D012636:Secretory Rate / Q000187:drug effects; D013268:Stimulation, Chemical; D013997:Time Factors
D004873:Ergolines; D006834:Hydrazines; D008711:Metergoline; D001971:Bromocriptine; D007980:Levodopa; D001545:Benserazide; D011388:Prolactin; D008784:Methysergide